Gilead discontinues gastric cancer candidate andecaliximab

Gilead Sciences Inc. (NASDAQ:GILD) announced in its 3Q18 earnings that it discontinued development of andecaliximab for gastric cancer. The company said a Phase III trial showed a lack of benefit on ...